Biology Department, College of Education, Salahaddin University-Erbil.
Cell Mol Biol (Noisy-le-grand). 2023 Mar 31;69(3):103-112. doi: 10.14715/cmb/2023.69.3.14.
In this study, early adverse impacts that emerged after vaccination with each dose of these vaccines were compared from previously infected participants. Ant-SARS-CoV-2 spike-specific IgG and IgA antibodies produced by these three vaccines have been assessed using ELISA method at different time periodsꓼ including pre-vaccination, 25 days after the first shot of vaccination and 30 days after the second shot of vaccination with Pfizer-BioNTech, AstraZeneca, and Sinopharm vaccine. Overall, 150 previously infected cases were studied, 50 cases received Pfizer vaccine, 50 cases received AstraZeneca vaccine, and 50 cases received Sinopharm vaccine. The findings showed that a higher number of vaccinated participants with AstraZeneca and Pfizer vaccine had tired/fatigue/lethargy, headache, fever, and sore in arm at the first shot, but milder adverse effects, such as headaches, fever, and sore in arm, were detected in the data on the Sinopharm vaccine's adverse impacts. At the second dose, a lower number of vaccinated cases with AstraZeneca and Pfizer vaccine reported higher frequencies of the side effects. However, the results showed that the level of anti-spike-specific IgG and IgA antibodies produced by vaccinated patients with Pfizer vaccine increased compared to those who vaccinated with AstraZeneca and Sinopharm vaccine from 25 days after the first dose. From 30 days after the second dose, the IgG and IgA antibodies were significantly boosted in 97% of vaccinated patients with Pfizer vaccine compared to 92% of those who vaccinated with AstraZeneca vaccines and 60% of those who vaccinated with Sinopharm. In conclusion, these results confirmed that two doses of the Pfizer, and AstraZeneca vaccine induce a higher response of IgG and IgA antibodies than that induced by Sinopharm vaccines.
在这项研究中，比较了先前感染的参与者在接种这些疫苗的每剂后出现的早期不良影响。使用 ELISA 法评估了这三种疫苗在不同时间段产生的针对 SARS-CoV-2 刺突的 IgG 和 IgA 抗体，包括接种前、接种第一针后 25 天和接种第二针后 30 天的 Pfizer-BioNTech、阿斯利康和国药疫苗。共有 150 名先前感染的病例进行了研究，50 名病例接种了辉瑞疫苗，50 名病例接种了阿斯利康疫苗，50 名病例接种了国药疫苗。结果表明，在接种第一针时，更多的阿斯利康和辉瑞疫苗接种者出现疲倦/乏力/嗜睡、头痛、发热和手臂酸痛等副作用，但在国药疫苗的不良反应数据中，仅检测到轻微的头痛、发热和手臂酸痛等副作用。在第二针时，阿斯利康和辉瑞疫苗接种者的不良反应发生率较低，但报告的副作用频率更高。然而，结果表明，与接种阿斯利康和国药疫苗的患者相比，接种辉瑞疫苗的患者在接种第一针后 25 天产生的抗刺突特异性 IgG 和 IgA 抗体水平有所增加。从第二针接种后 30 天开始，接种辉瑞疫苗的患者中有 97%的 IgG 和 IgA 抗体显著增加，而接种阿斯利康疫苗的患者中有 92%，接种国药疫苗的患者中有 60%。总之，这些结果证实，两剂辉瑞和阿斯利康疫苗诱导的 IgG 和 IgA 抗体反应高于国药疫苗。
